US expands scope of Janssen’s Stelara
The new approval cover paediatric patients with plaque psoriasis
Read More
Tag: IL-23
Cosentyx successful in plaque psoriasis trial
The drug successfully modulates gene expression, leading to substantial improvement of inflammation.
Read More
AbbVie’s IL-23 blocker shows efficacy in psoriasis trial
An experimental therapy being developed by AbbVie for the treatment of patients with moderate to severe plaque psoriasis has hit key targets in a pivotal late-stage trial.
Read More
UK launch for Janssen’s novel psoriasis biologic Tremfya
Janssen has announced the launch of Tremfya in the UK for adults with moderate to severe plaque psoriasis, following a green light from European regulators.
Read More
Janssen brings psoriasis therapy guselkumab to the EMA
Janssen has filed its potential new psoriasis therapy guselkumab with the European Medicines Agency, hot on the heels of the drug’s submission in the US.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
